VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Aflunov
Vaccine Information
  • Product Name: prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
  • Tradename: Aflunov
  • Manufacturer: Novartis
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: Europe
  • Host Species for Licensed Use: Human
  • Antigen: A/Vietnam/1194/2004 (H5N1)-like strain (NIBRG-14) (Aflunov Product Info).
  • Adjuvant: MF59
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: 2°C - 8°C
  • Approved Age for Licensed Use: 18 years and older (Aflunov Product Info).
  • Contraindication: History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)) of this vaccine (Aflunov Product Info).
References
Aflunov Product Info: Aflunov Product Information [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002094/WC500101080.pdf]
AREPANRIX H1N1
Vaccine Information
  • Product Name: AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine
  • Tradename: AREPANRIX H1N1
  • Manufacturer: GlaxoSmithKline Inc.
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: Canada
  • Host Species for Licensed Use: Human
  • Antigen: Split influenza virus, inactivated, containing antigen equivalent to: A/California/7/2009 (H1N1)v-like strain (X-179A) 3.75μg HA per 0.5mL dose (Health Canada DPD).
  • Adjuvant: AS03
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store at 2°C to 8°C (in a refrigerator).
  • Approved Age for Licensed Use: Adults aged 18-60 years
References
Health Canada DPD: Health Canada Drug Product Database [http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php]
Avaxim
Vaccine Information
  • Product Name: Hepatitis A vaccine (inactivated, adsorbed)
  • Tradename: Avaxim
  • Manufacturer: Sanofi Pasteur Ltd
  • Vaccine Ontology ID: VO_0010706
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: Canada
  • Host Species for Licensed Use: Human
  • Adjuvant: aluminum hydroxide vaccine adjuvant
  • Preservative: 2 phenoxy ethanol
  • Allergen: Neomycin
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: The vaccine must be stored in a refrigerator between 2°C and 8°C (EMC: Avaxim).
  • Approved Age for Licensed Use: 16 years and older (EMC: Avaxim)
  • Description: Products: Killed virus. Other components: Formaldehyde.
References
EMC: Avaxim: The electronic Medicines Compendium: Avaxim [http://emc.medicines.org.uk/medicine/17385/PIL/AVAXIM/]
Avaxim - Pediatric
Vaccine Information
  • Product Name: Hepatitis A Vaccine Inactivated
  • Tradename: Avaxim - Pediatric
  • Manufacturer: Sanofi Pasteur Ltd
  • Vaccine Ontology ID: VO_0010707
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: Canada
  • Host Species for Licensed Use: Human
  • Adjuvant: aluminum hydroxide vaccine adjuvant
  • Preservative: 2 phenoxy ethanol
  • Allergen: Neomycin
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store at 2˚ to 8˚C (35˚ to 46˚ F). Do not freeze (SP: Avaxim Pediatrix).
  • Approved Age for Licensed Use: 1 to 15 years of age (SP: Avaxim Pediatrix)
  • Description: Products: Killed virus. Other components: Formaldehyde.
References
SP: Avaxim Pediatrix: SP: Avaxim Pediatrix [https://www.vaccineshoppecanada.com/secure/pdfs/ca/Avaxim_Ped_E.pdf]
BVDV Inactivated Vaccine
Vaccine Information
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Antigen: BVDV PT810 and BVDV 890 (Beer et al., 2000).
  • Adjuvant: BAY R1005
  • Immunization Route: Intramuscular injection (i.m.)
References
Beer et al., 2000: Beer M, Hehnen HR, Wolfmeyer A, Poll G, Kaaden OR, Wolf G. A new inactivated BVDV genotype I and II vaccine. An immunisation and challenge study with BVDV genotype I. Veterinary microbiology. 2000; 77(1-2); 195-208. [PubMed: 11042413].
Cervarix
Vaccine Information
  • Product Name: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
  • Tradename: Cervarix
  • Manufacturer: GlaxoSmithKline Biologicals
  • Vaccine Ontology ID: VO_0011559
  • CDC CVX code: 118
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Adjuvant: AS04 vaccine adjuvant
  • Preparation: prepared by combining the adsorbed VLPs of each HPV type together with the AS04 adjuvant system in sodium chloride, sodium dihydrogen phosphate dihydrate, and water for Injection (FDA: Cevarix).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
  • Approved Age for Licensed Use: Females ages 10 to 25
References
FDA: Cevarix: FDA: Cervarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm]
Fluad
Vaccine Information
  • Product Name: Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1
  • Tradename: Fluad®
  • Manufacturer: Novartis
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: Canada, Europe
  • Host Species for Licensed Use: Human
  • Adjuvant: MF59
  • Allergen: Eggs, neomycin, kanomycin (Fluad Product Monograph)
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: 2°C to 8°C
  • Approved Age for Licensed Use: Persons aged 65 years and older (Fluad Product Monograph).
  • Description: Fluad is a trivalent, surface antigen, inactivated influenza virus vaccine adjuvanted with MF59C.1 (Fluad Product Monograph).
References
Fluad Product Monograph: Fluad Product Monograph [http://www.novartis.ca/products/en/vaccines-f.shtml]
Focetria
Vaccine Information
  • Product Name: Influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted
  • Tradename: Focetria
  • Manufacturer: Novartis
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: Europe
  • Host Species for Licensed Use: Human
  • Antigen: Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/California/07/2009 (H1N1)-derived strain used NYMC X-181 (Focetria Product Information).
  • Adjuvant: MF59
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Keep refrigerated
  • Approved Age for Licensed Use: Ages 6 months and older.
  • Contraindication: History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)) of this vaccine (Focetria Product Information).
References
Focetria Product Information: Focetria Summary of Product Characteristics [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000710/WC500023749.pdf]
FSME-IMMUN
Vaccine Information
  • Product Name: Tick-borne encephalitis vaccine, inactivated
  • Tradename: FSME-IMMUN
  • Manufacturer: Baxter
  • Vaccine Ontology ID: VO_0011560
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: Canada
  • Host Species for Licensed Use: Human
  • Adjuvant: aluminum hydroxide vaccine adjuvant
  • Allergen: eggs, gentamicin, neomycin, protamine sulfate
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: FSME-IMMUN should be stored between +2°C to +8°C.
  • Approved Age for Licensed Use: Adults (18 years of age and older)
References
 
Havrix
Vaccine Information
  • Product Name: Hepatitis A Vaccine, Inactivated
  • Tradename: Havrix
  • Manufacturer: GlaxoSmithKline Biologicals
  • Vaccine Ontology ID: VO_0000052
  • CDC CVX code: 52, 83
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1617), Canada
  • Host Species for Licensed Use: Human
  • Antigen: Hepatitis A Vaccine, Inactivated
  • Adjuvant: aluminum vaccine adjuvant
    • VO ID: VO_0000884
    • Description: Aluminum hydroxide
  • Preservative: 2 phenoxy ethanol (PE)
  • Preparation: HAVRIX (Hepatitis A Vaccine) is a sterile suspension of inactivated virus for intramuscular administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. After removal of the cell culture medium, the cells are lysed to form a suspension. This suspension is purified through ultrafiltration and gel permeation chromatography procedures. Treatment of this lysate with formalin ensures viral inactivation. Viral antigen activity is detected by ELISA and expressed in terms of ELISA Units (EL.U.) (FDA: Havrix).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store refrigerated between 2° and 8°C (36° and 46°F) (FDA: Havrix).
  • Approved Age for Licensed Use: Ages greater than 12 months (FDA: Havrix).
  • Contraindication: HAVRIX can cause a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis A-containing vaccine, or to any component of HAVRIX, including neomycin. Hepatitis A vaccine may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination (FDA: Havrix).
  • Description: Indication: To support lowering the age indication for Havrix from two years to 12 months of age (FDA: Havrix).
References
FDA: Havrix: FDA: Havrix vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110016.htm]
Inactivated H1N1(2009) Vaccine with AF03 adjuvant
Vaccine Information
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Adjuvant: AF03 vaccine adjuvant
  • Immunization Route: Intramuscular injection (i.m.)
References
 
Inactivated HIV-2 Vaccine with PMMA
Vaccine Information
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Adjuvant: PMMA
  • Immunization Route: subcutaneous injection
References
 
Inactivated PMV-3 Vaccine with Specol
Vaccine Information
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Antigen: formalin inactivated PMV-3 strain 1388/84 (Beck et al., 2003).
  • Adjuvant: Specol
  • Immunization Route: Intramuscular injection (i.m.)
References
Beck et al., 2003: Beck I, Gerlach H, Burkhardt E, Kaleta EF. Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3. Vaccine. 2003; 21(9-10); 1006-1022. [PubMed: 12547615].
Inactivated split Mem 71 Virus with SPT adjuvant
Vaccine Information
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Antigen: Inactivated Mem 71virus (A/Memphis/l/71 x A/Bellamy/42 (H3N1) recombinant) (Deliyannis et al., 1998).
  • Adjuvant: SPT (Antigen Formulation)
  • Immunization Route: subcutaneous injection
References
Deliyannis et al., 1998: Deliyannis G, Jackson DC, Dyer W, Bates J, Coulter A, Harling-McNabb L, Brown LE. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine. 1998; 16(20); 2058-2068. [PubMed: 9796065].
Ixiaro
Vaccine Information
  • Product Name: Japanese Encephalitis Vaccine, Inactivated, Adsorbed
  • Tradename: IXIARO
  • Manufacturer: Intercell Biomedical
  • Vaccine Ontology ID: VO_0011558
  • CDC CVX code: 134
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Adjuvant: aluminum hydroxide vaccine adjuvant
  • Preparation: JEV strain SA14-14-2 is propagated in Vero cells, and harvested. The harvested virus suspension is treated with protamine sulfate to remove contaminating DNA and proteins and centrifuged. Virus is inactivated by formaldehyde and aluminum hydroxide is added Ref917:FDA: Ixiaro].
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store in a refrigerator at 2° to 8° C (35° to 46° F). Do not freeze.
  • Approved Age for Licensed Use: 17 years of age and older
References
 
Killed Vaccinia Virus with Adjuvant NanoEmulsion
Vaccine Information
  • Type: Inactivated or "killed" vaccine
  • Antigen: Two strains of vaccinia virus (VV) were used for antigens: VV Western Reserve strain (VVWR) and recombinant Western Reserve strain (VVWR-Luc). The recombinant strain is the same as the VVWR except for expression of firefly luciferase from the pH 7.5 early/late promoter (Bielinska et al., 2008).
  • Adjuvant: nanoemulsion vaccine adjuvant
  • Preparation: The viruses killed by incubation were incubated for 3 h at 37°C in 10% NE. Nasal instillation killed virus was diluted to obtain either 1 x 103 PFU or 1 x 105 PFU per dose in 1% NE. Vaccine formulations containing formalin-killed virus (Fk) were prepared by incubation of VV (about 108 PFU/ml) with 0.1% formalin at room temperature for 3 h. This mixture was then diluted in either saline or 1% NE to 1 x 103 or 1 x 105 PFU per dose to reduce the formalin to nontoxic concentrations for intranasal (i.n.) immunization (Bielinska et al., 2008).
References
Bielinska et al., 2008: Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, Baker JR Jr. A novel, killed-virus nasal vaccinia virus vaccine. Clinical and vaccine immunology : CVI. 2008; 15(2); 348-358. [PubMed: 18057181].
Mutagrip Vaccine with P40 Adjuvant
Vaccine Information
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Adjuvant: Corynebacterium-derived P40 vaccine adjuvant
  • Immunization Route: subcutaneous injection
References
 
Porcilis-PCV2
Vaccine Information
  • Tradename: Porcilis-PCV2
  • Manufacturer: Intervet
  • Vaccine Ontology ID: VO_0000201
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Pig
  • Adjuvant: incomplete Freund's adjuvant
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Inactivated baculovirus expressed PCV2 ORF2 protein; adjuvanted (Wang et al., 2007).
References
Wang et al., 2007: Wang X, Jiang P, Li Y, Jiang W, Dong X. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. Veterinary microbiology. 2007; 121(3-4); 215-224. [PubMed: 17215092].
Rabies Vaccine Adsorbed (RVA)
Vaccine Information
  • Product Name: Rabies Vaccine Adsorbed
  • Tradename: None
  • Manufacturer: BioPort Corp
  • Vaccine Ontology ID: VO_0000095
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Antigen: Inactivated Kissling strain of Challenge Virus Standard (CVS) rabies virus.
  • Adjuvant: aluminum phosphate vaccine adjuvant
    • VO ID: VO_0000128
    • Description: BioPort's Rabies Vaccine is effective for pre- and post-exposure indications, and is administered intramuscularly (not intradermally). However, this vaccine is no longer available for rabies postexposure or pre-exposure prophylaxis, and intradermal pre-exposure prophylaxis is no longer recommended because it is not available in the United States (Manning et al., 2008).
  • Preparation: Rabies Vaccine Adsorbed (RVA) is an aqueous formulation of rabies virus cultured in diploid fetal rhesus lung (FRhL-2) cells, inactivated with beta-propiolactone (BPL), and adsorbed on aluminum phosphate adjuvant. The vaccine is prepared from the Kissling strain of Challenge Virus Standard (CVS) rabies virus adapted to fetal rhesus lung diploid cell culture. The inactivated virus is concentrated by adsorption onto aluminum phosphate adjuvant.
  • Description: BioPort's Rabies Vaccine is effective for pre- and post-exposure indications, and is administered intramuscularly (not intradermally). However, this vaccine is no longer available for rabies postexposure or pre-exposure prophylaxis, and intradermal pre-exposure prophylaxis is no longer recommended because it is not available in the United States (Manning et al., 2008).
References
Manning et al., 2008: Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2008; 57(RR-3); 1-28. [PubMed: 18496505].